Jiangsu Vcare Pharmaceutical Technology Co., Ltd

This phase 3 trial tests whether VC005 tablets can reduce symptoms of active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 420 adults aged 18 to 70 will receive either VC005 or a placebo for 48 weeks. The main goal is to see how many achieve a 2…

This study tests a new drug called VC005 in 120 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants will take either VC005 or a placebo daily for 52 weeks. The main goal is to see if the drug can reduce the size of white patches on …